Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Pauline dlp
    Junior Member
    • Mar 2018
    • 8

    Methylation-sensitive restriction enzymes for GBS

    Hi all!

    I need help in selecting a restriction enzyme for GBS. Elshire's protocol for GBS calls for methylation-sensitive enzymes (They used ApeKI). He also underscores this in GBS workshops. I understand the use of methylation-sensitive REs is to filter out repetitive regions and to enrich genic regions, right?

    Now here is where I am confused. I went out to search for literature for GBS done on insects (as I will be studying silkworm genomics), and found that some GBS studies use non-methylation-sensitive REs.

    [1] Silva-Brandão et al in 2015, used PstI and MspI (double enzyme GBS) for oriental fruit moth. PstI and MspI are both NOT methylation sensitive.

    [2] Dupuis et al in 2017 used PstI and MspI for GBS of the North American spruce budworm.

    They both cited Poland 2012 for double digest GBS using PstI and MspI.


    So does this mean methylation-sensitive REs are not required for GBS after all? What would be the consequences of choosing a methylation-insensitive vs. methylation-sensitive enzyme for GBS?
  • nucacidhunter
    Jafar Jabbari
    • Jan 2013
    • 1250

    #2
    Methylation sensitive enzymes are more useful for plants as their genome contains large repetitive regions due to duplication events. PstI is methylation sensitive in plants as in plants methylation normally is in non-CpG context.

    Choosing methylation insensitive RE can result in sequencing non-informative tags from repeat regions increasing the cost and has no other consequence. But this will depend on the genome and I do not think it would be a concern for non-plant species.

    If you have access to Pippin instrument ddRAD would be a better choice.

    Comment

    • Pauline dlp
      Junior Member
      • Mar 2018
      • 8

      #3
      Thanks for the reply, nucacidhunter! So it seems methylation sensitivity is more of an issue for plants. I tried doing in silico digests of my reference genome with several REs, and the methylation insensitive ones give a decent number of fragments for the target size (~100-200 bp).

      We do have a PippinPrep, would bring up the possibility of using ddRAD. But i'm not sure I could do that since the project proposal stated GBS methods will be used.

      Comment

      • nucacidhunter
        Jafar Jabbari
        • Jan 2013
        • 1250

        #4
        GBS is a common name used for even non-restriction enzyme based methods. For instance, Illumina recently released a GBS kit that prepares libraries without RE o. ddRAD generally results in good coverage of tags as there is good control over tag numbers.

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          Today, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, Today, 11:10 AM
        0 responses
        7 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        29 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-09-2026, 10:04 AM
        0 responses
        38 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-08-2026, 10:08 AM
        0 responses
        25 views
        0 reactions
        Last Post SEQadmin2  
        Working...